CA2496572A1 - Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs - Google Patents
Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs Download PDFInfo
- Publication number
- CA2496572A1 CA2496572A1 CA002496572A CA2496572A CA2496572A1 CA 2496572 A1 CA2496572 A1 CA 2496572A1 CA 002496572 A CA002496572 A CA 002496572A CA 2496572 A CA2496572 A CA 2496572A CA 2496572 A1 CA2496572 A1 CA 2496572A1
- Authority
- CA
- Canada
- Prior art keywords
- carbonic anhydrase
- residues
- antibody
- seq
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
L'invention concerne des compositions et des procédés utiles pour inhiber la prolifération de cellules prénéoplastique ou néoplastiques CA IX + chez un mammifère. Ces compositions sont des anticorps anti-CA IX et d'autres agents inhibiteurs qui ciblent l'activité d'anhydrase carbonique sur ces cellules. Ces anticorps anti-CA IX antagonistes ou fragments de liaison d'antigène de ces derniers réagissent de manière spécifique avec un épitope inhibiteur de CA IX ou un variant biologiquement actif de celui-ci. La formation d'un complexe anticorps-antigène entre les anticorps anti-CA IX antagonistes ou les fragments de liaison d'antigène de ce dernier et les épitopes inhibiteurs respectifs, entraîne l'inhibition de l'activité d'anhydrase carbonique de CA IX ou d'un variant biologiquement actif de ce dernier. L'invention porte sur d'autres agents à petites molécules qui inhibent l'activité d'anhydrase carbonique de CA IX ou d'un variant biologiquement actif de ce dernier et sur des dosages de criblage permettant d'identifier ces agents. Les anticorps anti-CA IX antagonistes, les fragments de liaison d'antigène de ce dernier, et d'autres agents inhibiteurs de CA IX susmentionnés sont utiles dans le traitement de cancers caractérisés par l'expression de l'antigène CA IX associé aux tumeurs.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40557702P | 2002-08-23 | 2002-08-23 | |
US60/405,577 | 2002-08-23 | ||
US64693403A | 2003-08-22 | 2003-08-22 | |
US10/646,934 | 2003-08-22 | ||
PCT/US2003/026612 WO2004017923A2 (fr) | 2002-08-23 | 2003-08-25 | Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2496572A1 true CA2496572A1 (fr) | 2004-03-04 |
Family
ID=31949897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002496572A Abandoned CA2496572A1 (fr) | 2002-08-23 | 2003-08-25 | Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1576010A4 (fr) |
JP (1) | JP2005536220A (fr) |
AU (1) | AU2003268180A1 (fr) |
CA (1) | CA2496572A1 (fr) |
WO (1) | WO2004017923A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487972B1 (fr) | 2002-02-21 | 2015-08-12 | Institute Of Virology | Anticorps monoclonaux specifiques de la proteine mn/ca ix generes a partir de souris carentes en mn/ca ix, et methodes d'utilisation |
US7833734B2 (en) | 2002-11-26 | 2010-11-16 | Institute Of Virology Of The Slovak Academy Of Sciences | CA IX-specific inhibitors |
DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
WO2008091798A2 (fr) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Anticorps de ca9 optimises et methodes d'utilisation associees |
CA2708281A1 (fr) * | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Inhibiteurs de metalloenzymes utilisant des fractions de liaison a un metal en combinaison avec des fractions de ciblage |
CN114127120A (zh) * | 2019-05-06 | 2022-03-01 | 纳维再生科技股份有限公司 | 抗-碳酸酐酶ix抗体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955075A (en) * | 1992-03-11 | 1999-09-21 | Institute Of Virology, Slovak Academy Of Sciences | Method of inhibiting tumor growth using antibodies to MN protein |
DK1123387T3 (da) * | 1998-10-23 | 2008-02-25 | Inst Virology | MN-gen og protein |
-
2003
- 2003-08-25 JP JP2004531195A patent/JP2005536220A/ja not_active Withdrawn
- 2003-08-25 CA CA002496572A patent/CA2496572A1/fr not_active Abandoned
- 2003-08-25 EP EP03749129A patent/EP1576010A4/fr not_active Withdrawn
- 2003-08-25 WO PCT/US2003/026612 patent/WO2004017923A2/fr active Application Filing
- 2003-08-25 AU AU2003268180A patent/AU2003268180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005536220A (ja) | 2005-12-02 |
AU2003268180A8 (en) | 2004-03-11 |
WO2004017923A3 (fr) | 2005-07-14 |
EP1576010A4 (fr) | 2006-12-27 |
AU2003268180A1 (en) | 2004-03-11 |
EP1576010A2 (fr) | 2005-09-21 |
WO2004017923A2 (fr) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018236755B2 (en) | Anti-folate receptor alpha antibodies and uses thereof | |
US20180319891A1 (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
JP2009531031A (ja) | 抗−腫瘍細胞抗原抗体療法 | |
US20160130344A1 (en) | Anti-gcc antibody molecules and methods for use of same | |
CN107250160B (zh) | 人源化cc趋化因子受体4 (ccr4)抗体及其使用方法 | |
JP2004520806A (ja) | 腫瘍の診断と治療のための組成物と方法 | |
JP2004537534A (ja) | 腫瘍の診断及び治療のための組成物及び方法 | |
US10787516B2 (en) | Antibodies that bind to AXL proteins | |
JP2009527507A (ja) | Cd63の表面発現を示す細胞に対する細胞傷害性介入 | |
KR102550489B1 (ko) | 암 진단에 유용한 항체 | |
KR20090029276A (ko) | 헵신을 표적화하기 위한 방법 및 조성물 | |
JP2004520810A (ja) | 腫瘍の診断と治療のための組成物と方法 | |
US20090252738A1 (en) | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix | |
KR20110031438A (ko) | 변이체 hhip1 단백질 및 방법 및 그의 용도 | |
CA2496572A1 (fr) | Compositions et procedes therapeutiques contre les cancers caracterises par l'expression de l'antigene mn/ca ix associe aux tumeurs | |
US10787517B2 (en) | Antibodies that bind to AXL proteins | |
KR101789338B1 (ko) | 이소형 특이적 항-her4 항체 | |
US20070237772A1 (en) | Tumor association of mdl-1 and methods | |
CN115515625A (zh) | 与人类ceacam1/3/5特异性结合的新抗体及其用途 | |
US20040258696A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2004324192A1 (en) | Method for treating tumors using anti-osteopontin antibodies | |
JP2004520808A (ja) | 腫瘍の診断と治療のための組成物と方法 | |
JP2022512644A (ja) | フィラミンaに対する抗体およびその治療上の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |